联合用药治疗肝纤维化的研究概况与展望  

Developments in research on combination drugs for hepatic fibrosis

作　　者：申雪 江海燕 范潇予 李万芳[2,3] 包捷 何博赛[1] 靳洪涛 SHEN Xue;JIANG Haiyan;FAN Xiaoyu;LI Wanfang;BAO Jie;HE Bosai;JIN Hongtao(Faculty of Functional Food and Wine,Shenyang Pharmaceutical University,Shenyang Liaoning 110016,China;New Drug Safety Evaluation Center,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China;Beijing Union-Genius Pharmaceutical Technology Development Co.,Ltd.,Beijing 100176,China;NMPA Key Laboratory for Safety Research and Evaluation of Innovative Drug,Beijing 102206,China)

机构地区：[1]沈阳药科大学功能食品与葡萄酒学院,辽宁沈阳110016 [2]中国医学科学院北京协和医学院药物研究所新药安全评价研究中心,北京100050 [3]北京协和建昊医药技术开发有限责任公司,北京100176 [4]国家药品监督管理局创新药物安全研究与评价重点实验室,北京102206

出　　处：《中国药物警戒》2024年第9期985-990,共6页Chinese Journal of Pharmacovigilance

基　　金：国家自然科学基金资助项目(82074104);中国毒理学会临床毒理学转化研究课题(CST2021CT101)。

摘　　要：目的探讨联合用药在肝纤维化(HF)治疗领域的研究现状以及未来展望。方法回顾国内外相关文献,总结该领域的研究成果,讨论HF治疗的关键问题,包括发病机制、现有药物治疗方法及联合用药治疗的主要进展。结果HF的发病机制主要涉及肝星状细胞激活、铁死亡、细胞自噬以及细胞传导通路。目前应用的单药治疗虽然在控制病情上取得了一定成效,但治疗效果有限且可能面临药物耐药性等问题。联合用药由于其多靶点、多途径的作用机制,已成为治疗HF的研究热点。国内外研究表明,某些联合用药能够显著抑制病理过程、改善肝功能指标,且在减轻HF、提高预后方面作用突出。结论多药物联合治疗是治疗HF的有效策略之一,尤其在处理复杂病理机制和多因素影响的情况下作用突出。建议未来研究进一步优化联合治疗方案,复方药物开发可能成为新药研究的新趋势。Objective To summarize the current research and prospects of drug combinations used in the treatment of hepatic fibrosis(HF).Methods Related literature at home and abroad was reviewed,research findings in this field were summarized,and the key issues facing HF treatment were discussed,including the pathogenesis,medications currently used and the progress in drug combination therapies.Results The pathogenesis of HF involved hepatic stellate cell activation,iron death,autophagy and cell conduction pathway.Despite the benefits of monotherapy in controlling the disease,the therapeutic effect was limited and such problems as drug resistance existed.Because of the multi-target and multi-pathway mechanism of action,drug combinations became a hot spot in the treatment of HF.Studies showed that some drug combinations could significantly inhibit pathological processes,improve liver function indexes,and go a long way towards alleviating HF and improving prognosis.Conclusion Multi-drug combination therapies are one of the effective strategies for HF treatment,especially in case of complex pathological mechanism and multi-factor influence.It is recommended that future studies continue to optimize the combination treatment regimens.The development of compound drugs may become a new trend in new drug research.

关 键 词：肝纤维化 肝星状细胞 细胞外基质 发病机制 联合用药 复方药物 

分 类 号：R916[医药卫生—药学] R975